Efficacy and Feasibility of Cisplatin-Based Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma*

(80 mg/m 2 ) were scheduled during 70 Gy of radiotherapy (RT), and two agents of adjuvant chemotherapy (FP regimen: cisplatin 80 mg/m 2 and 5-fluorouracil 800 mg/m 2 /day by 4-day continuous infusion) were challenged. Overall survival (OS) and relapse-free survival (RFS) rates were calculated by the Kaplan–Meier method. Results: Median follow-up duration was 45 months. Both 3-year OS and RFS rates were 81%. Proportions of patients who tolerated each scheduled treatment were 94% for RT, 63% for concurrent chemotherapy and 38% for adjuvant chemotherapy. Conclusions: Our protocol of the cisplatin-based concurrent CRT followed by adjuvant chemotherapy consisting of FP regimen was effective for Japanese patients with NPC. However, the dosesandnumbersofcycleofchemotherapyneedtobemodifiedbecauseofthelowcompliance rate. Larger numbers of data accumulation and/or multi-institutional trials may be warranted to confirm the efficacy of this protocol.